U.S. markets closed
  • S&P Futures

    4,126.75
    +2.25 (+0.05%)
     
  • Dow Futures

    32,759.00
    +22.00 (+0.07%)
     
  • Nasdaq Futures

    13,036.75
    +5.25 (+0.04%)
     
  • Russell 2000 Futures

    1,915.30
    +0.70 (+0.04%)
     
  • Crude Oil

    90.63
    +0.13 (+0.14%)
     
  • Gold

    1,808.90
    -3.40 (-0.19%)
     
  • Silver

    20.49
    +0.00 (+0.01%)
     
  • EUR/USD

    1.0213
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    2.7970
    +0.0320 (+1.16%)
     
  • Vix

    21.77
    +0.48 (+2.25%)
     
  • GBP/USD

    1.2075
    -0.0001 (-0.01%)
     
  • USD/JPY

    135.0560
    -0.0600 (-0.04%)
     
  • BTC-USD

    22,893.01
    -858.44 (-3.61%)
     
  • CMC Crypto 200

    532.24
    -25.11 (-4.51%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,840.35
    -159.61 (-0.57%)
     

Novocure Posts Data For Tumor Treating Fields In Brain Tumor Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Novocure Ltd (NASDAQ: NVCR) has released updated data from the Phase 2 pilot 2-THE-TOP of Tumor Treating Fields (TTFields) together with pembrolizumab and temozolomide for newly diagnosed glioblastoma (GBM).

  • Of the 19 patients with follow-up over nine months, the median progression-free survival was at least 11.2 months compared to 6.7 months from the historical control study (EF-14), in which patients received TTFields and adjuvant temozolomide.

  • Twelve (48%) were progression-free, and 15 (60%) were still alive. Six (24%) patients with measurable tumors achieved partial or complete response.

  • The most common adverse events were thrombosis (4 patients, 16%), seizure (3 patients, 12%), and metabolic disturbances (2 patients, 8%).

  • Related Link: Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer.

  • Price Action: NVCR shares are down 1.96% at $112.81 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.